Zentalis Pharmaceuticals, Inc. (ZNTL) Tops Q2 EPS by 17c
Tweet
Share
E-mailGet Alerts ZNTL Hot Sheet
Join SI Premium – FREE
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) reported Q2 EPS of ($0.37), $0.17 better than the analyst estimate of ($0.54).
For earnings history and earnings-related data on Zentalis Pharmaceuticals, Inc. (ZNTL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Momo (MOMO) Tops Q2 EPS by 8c; offers guidance
- BNP Paribas Exane Starts NTPC Ltd (NTPC:IN) at Outperform
- Barrick Mining said to delay IPO of American gold business to 2027
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
